For instance, Da Mesquita et al. reported that VEGF-C delivery improved the outcome of 5 × FAD mice undergoing anti-Aβ passive immunotherapy by reducing Aβ deposits and other AD-related pathology, suggesting synergistic therapeutic potential of lymphangiogenic treatment and Aβ-immunotherapy [104]. This evidence concerns the gene VEGFC and Alzheimer disease.